What is the clinical significance and recommended management of a prominent U wave in lead II in a non‑hypothermic patient?

U Wave in Lead II (Non-Hypothermic Patient)

A prominent U wave in lead II of a non-hypothermic patient warrants immediate evaluation for hypokalemia, cardiac ischemia (particularly posterior wall), and QT-prolonging medications, as these represent the most clinically significant and actionable causes.

Clinical Significance

The U wave is a low-amplitude deflection following the T wave that becomes more prominent with bradycardia (present in 90% of cases at heart rates <65 bpm) and is typically most visible in precordial leads V2-V3 rather than limb leads 1. When a U wave is prominent in lead II specifically, this represents an abnormal finding requiring investigation.

Key Pathological Associations

Hypokalemia is the most critical immediate concern:

• U-wave amplitude increases with decreasing potassium levels
• When K+ <2.7 mmol/L, U-wave amplitude may exceed T-wave amplitude in the same lead
• This may actually represent fusion of the U wave with the T wave rather than true U-wave enlargement 1
• Check serum potassium immediately

Cardiac ischemia, particularly posterior wall:

• Prominent U waves in right precordial leads (V1-3) during angina suggest posterobasal ischemia and critical stenosis of the circumflex or right coronary artery 2, 3
• This can occur with silent ischemia, making ECG findings the only diagnostic clue 3
• While your question specifies lead II, consider evaluating precordial leads for additional U-wave changes

Medication effects:

• Cardioactive drugs with quinidine-like effects increase U-wave amplitude, typically associated with ST depression and decreased T-wave amplitude 1
• Review all QT-prolonging medications

Increased sympathetic tone:

• Can cause fusion of U wave with T wave 1

Recommended Management Algorithm

1. Immediate laboratory assessment:

   • Serum potassium, magnesium, calcium
   • If hypokalemia confirmed, initiate appropriate replacement

2. Medication review:

   • Identify and consider discontinuing QT-prolonging or quinidine-like drugs
   • Calculate QTc to assess for prolonged repolarization 4

3. Ischemia evaluation:

   • Assess for chest pain or anginal equivalents
   • Compare with prior ECGs to determine if U-wave prominence is new
   • Examine precordial leads V1-3 for additional prominent U waves suggesting posterior ischemia
   • If ischemia suspected, proceed with stress testing or coronary imaging 2, 3

4. Assess for inverted U waves:

   • Inverted U waves in V2-V5 are always abnormal and suggest acute ischemia or hypertension 1
   • This is a more specific marker than prominent upright U waves

Critical Pitfalls

• Don't overlook subtle U waves: They are frequently missed by both automated systems and human readers 1
• Don't confuse T-U fusion with isolated U-wave prominence: These represent different pathophysiology 1
• Don't ignore the clinical context: U waves are heart-rate dependent and rarely present at rates >95 bpm 1
• Document the finding: Per AHA/ACCF/HRS guidelines, statements concerning U waves should be included in ECG interpretation when inverted, merged with T wave, or when amplitude exceeds the T wave 1

When to Report

The guideline explicitly states that U-wave findings should be documented when: the U wave is inverted, merged with the T wave, or its amplitude is greater than the T wave 1. A prominent U wave in lead II (where U waves are typically absent or minimal) meets criteria for documentation and clinical follow-up.